300511.SHE Shanghai Xuerong Bio-Technology Co Ltd
- Market cap
- CNY 2.63B
- P/E
- 45.6x
- P/B
- 1.61x
- ROE
- -4.0%
- Dividend yield
- 1.62%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300511.SHE undervalued?
Graham number300511.SHE trades 80.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Xuerong Bio-Technology Co Ltd fundamental analysis
No fundamental analysis for Shanghai Xuerong Bio-Technology Co Ltd yet.
Shanghai Xuerong Bio-Technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Xuerong Bio-Technology Co Ltd
Shanghai Xuerong Biotechnology Co., Ltd., together with its subsidiaries, engages in the research, development, cultivation, and sale of edible fungi in China and internationally. It offers enoki, white jade, crab, seafood, king oyster, shiitake, deer antler, and nameko mushrooms. The company was founded in 1995 and is based in Shanghai, China.
Full company profileShanghai Xuerong Bio-Technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Xuerong Bio-Technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 999M | 1.33B | 1.85B | 1.96B | 2.20B | 2.06B | 2.32B | 2.57B | 2.16B | 1.99B | 2.26B |
| Gross Profit | 230M | 264M | 264M | 431M | 481M | 109M | 248M | 215M | 78.0M | 271M | 308M |
| Operating Income | 93.4M | 109M | 45.2M | 206M | 306M | -64.2M | 100M | -41.8M | -99.9M | 98.9M | 135M |
| EBITDA | - | 354M | 479M | 570M | 616M | 38.4M | 53.7M | 221M | -144M | 438M | -29.0M |
| Net Income | 105M | 122M | 151M | 220M | 247M | -309M | -287M | -188M | -617M | 29.8M | -63.2M |
| EPS | - | 0.28 | 0.35 | 0.51 | 0.56 | -0.70 | -0.57 | -0.38 | -1.24 | 0.05 | -0.10 |
| Balance Sheet | |||||||||||
| Total Assets | 2.46B | 3.84B | 3.89B | 3.84B | 4.56B | 4.34B | 4.07B | 4.60B | 3.85B | 3.60B | 3.50B |
| Total Liabilities | 1.17B | 2.42B | 2.32B | 2.10B | 2.54B | 2.69B | 2.45B | 3.17B | 3.03B | 2.09B | 2.02B |
| Shareholders' Equity | 1.28B | 1.39B | 1.57B | 1.74B | 2.03B | 1.67B | 1.74B | 1.55B | 939M | 1.61B | 1.58B |
| Cash & Short-term Investments | 165M | 240M | 381M | 288M | 760M | 341M | 364M | 253M | 168M | 161M | 128M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 318M | 329M | 407M | 587M | 555M | 247M | 367M | 358M | 437M | 416M | - |
| Capital Expenditure | 695M | 1.18B | 442M | 312M | 483M | 640M | 319M | 1.10B | 327M | 79.6M | 295M |
| Free Cash Flow | - | -873M | -35.4M | 275M | 72.7M | -393M | 47.7M | -739M | 110M | 336M | 86.1M |
| Ratios | |||||||||||
| ROE | 8.2% | 8.8% | 9.7% | 12.7% | 12.2% | -18.5% | -16.5% | -12.1% | -65.7% | 1.8% | -4.0% |
| ROA | 4.3% | 3.2% | 3.9% | 5.7% | 5.4% | -7.1% | -7.1% | -4.1% | -16.0% | 0.8% | -1.8% |
| Net Profit Margin | 10.5% | 9.2% | 8.2% | 11.2% | 11.2% | -15.0% | -12.4% | -7.3% | -28.5% | 1.5% | -2.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Xuerong Bio-Technology Co Ltd dividends
- Dividend yield
- 1.62%
- Forward dividend
- -
- Payout ratio
- 143.2%
- Ex-dividend date
- May 14, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 42.7M | 0.07 | 143.2% |
| 2024 | CNY 67.0M | 0.13 | - |
| 2023 | CNY 60.3M | 0.12 | - |
| 2022 | CNY 58.7M | 0.12 | - |
| 2021 | CNY 103M | 0.23 | - |
| 2020 | CNY 116M | 0.26 | 46.9% |
| 2019 | CNY 134M | 0.31 | 61.0% |
| 2018 | CNY 112M | 0.26 | 73.7% |
| 2017 | CNY 74.0M | 0.17 | 60.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.9:1 on Apr 23, 2018.
Who owns Shanghai Xuerong Bio-Technology Co Ltd
- Insiders 27.53%
- Institutions 1.72%
- Public & others 70.76%
- Shares outstanding 641M
- Free float 514M
Shanghai Xuerong Bio-Technology Co Ltd company profile
- Company name
- Shanghai Xuerong Bio-Technology Co Ltd
- Ticker
- 300511.SHE
- ISIN
- CNE100002706
- Exchange
- Shenzhen Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 1,920
- Fiscal year end
- December
- Address
- No. 1487 Huifeng West Road, Shanghai, China, 201401
- Phone
- 86 40 0820 7016
- Website
- xuerong.com
About Shanghai Xuerong Bio-Technology Co Ltd
Shanghai Xuerong Biotechnology Co., Ltd., together with its subsidiaries, engages in the research, development, cultivation, and sale of edible fungi in China and internationally. It offers enoki, white jade, crab, seafood, king oyster, shiitake, deer antler, and nameko mushrooms. The company was founded in 1995 and is based in Shanghai, China.
Shanghai Xuerong Bio-Technology Co Ltd management
4- Mr. Xueqiang ChenCFO & Accounting Supervisor · born 1970
- Mr. Weidong ZhengExecutive VP & Non-Independent Director · born 1970
- Mr. Yongkang GuBoard Secretary · born 1987
- Mr. Yong LuDeputy General Manager · born 1982